{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6Jqc8IDA","lastupdate":"2024-07-11T00:00:00.000Z","update_date":"2024-07-11T00:00:00.000Z","lastModified":"Sep 7, 2024","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"biogencell","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$aS2XYQbTtrPdtZop8CYJlfHTqbKJYqfoVuB9BUzepTXK3skNdHk42y","name":"BioGenCell","oneliner":"Stem Cell Therapy Platform for Degenerative Diseases","registrar":"514215250","website":"https://www.biogencell.net","careerspage":"","founded_month":12,"founded_year":2008,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"https://www.facebook.com/www.BioGenCell.net","linkedin":"https://www.linkedin.com/company/69232576","instagram":""},"social":["https://www.facebook.com/www.BioGenCell.net","https://www.linkedin.com/company/69232576"],"flattenedsociallinks":"https://www.facebook.com/www.BioGenCell.net|https://www.linkedin.com/company/69232576","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":15,"patent":1,"raised":18350000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's technology creates autologous cells, derived from the patients themselves, to repair themselves. \r\n\r\nBioGenCell's lead product, BC1, uses the company's technology to treat blood vessel insufficiency, which can cause multiple organ failure in diabetic patients. \r\n\r\nDerived from the patient's own adult stem cells, BioGenCell's easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases.\r\n\r\nBioGenCell's patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (biobanking) of therapeutic cellular products for use in patient treatment.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97298609248","country":null,"address":{"israeli":[{"id":"c2c5ca81-3aec-4361-8a77-ac32b881b99c","city":"Netanya","type":null,"address":"Divrei Khayim Street 16, Netanya, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"RR0yDl2xzzXprUVtaWBPvQP7Ohhdwc3lIpjZkQwhNsLsnn5ymBmhFk","date":"Dec 19, 2024","link":"https://www.prnewswire.com/il/news-releases/biogencell-receives-fda-fast-track-designation-with-expanded-access-for-bgc101-302336043.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA approval","company":"BioGenCell","layoffs":null,"summary":"BioGenCell, a leader in regenerative medicine, has been granted Fast Track Designation by the FDA for its lead candidate, BGC101, aimed at treating severe Critical Limb Threatening Ischemia (CLTI). This designation allows for accelerated clinical development and compassionate-use access for eligible patients. BGC101 uses BioGenCells proprietary TRACT platform to create personalized cell therapies from a patients own blood, promoting tissue regeneration and restoring blood flow. The company has completed patient recruitment for its Phase 2 clinical trial, which focuses on amputation-free survival and symptom relief. This milestone highlights the potential of BioGenCells innovative approach to address unmet medical needs in CLTI.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA approval","regenerative medicine","clinical trials","cell therapy","CLTI treatment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PHZkOWSbazTaMXbGzxdySGs59Jq6wjVdqRi3gBNXYBBa0nurKQ5PSB","news_summary":"/PRNewswire/ -- BioGenCell, a biotechnology leader in regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"pBIhNFi9H6lTjmzipgLQ0QRzlrUZe9YfbfpvmMWTiLwqn2Fv752Ep5","date":"Jul 11, 2024","link":"https://www.calcalistech.com/ctechnews/article/hki11xl2wa","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"biotech, cell therapy","company":"BioGenCell","layoffs":"Not mentioned","summary":"BioGenCell, an Israeli biotech company, is developing a cell therapy treatment for microvascular diseases, a common and debilitating illness often resulting from advanced diabetes. The companys treatment combines immune and stem cell therapies to produce personalized cell treatments using the patients own blood. The treatment has shown promising results, with a 100% amputation-free survival rate in Phase 1 trials. The company, which has raised a total of $16 million, is currently raising funds for its Phase 3 trials and plans to expand its manufacturing capabilities globally.","partners":"Yale, Johns Hopkins, Laniado hospital, Belgium, Georgia","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cell Therapy","Microvascular Diseases","Clinical Trials","Fundraising","Expansion"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$16 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9ulpARjuhPoXmgNG09gJdj5WDc7gxkpgeBamypi5k4x3jP8kRfCBKH","news_summary":"BioGenCell pioneers revolutionary cell therapy for microvascular disease | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e49d0653-c736-4922-8996-f97746649876","date":"May 9, 2022","link":"https://www.calcalistech.com/ctechnews/article/sywu8eil5","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"biotechnology, stem cells","company":"BioGenCell","layoffs":null,"summary":"Israeli biotechnology company BioGenCell has completed a $16 million Seed round led by private investor Marius Nacht. The company develops technology for using stem cells from the patient’s own blood to treat microvascular diseases. Their current product is intended for the treatment of chronic limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers. BioGenCell recently received FDA approval permission to continue to Phase II clinical trials.","partners":"Laniado Hospital","customers":null,"investors":"Marius Nacht","confidence":8,"key_topics":["Stem cells","Microvascular diseases","Chronic limb-threatening ischemia","Personalized medicine","Phase II clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$16 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mqeDPcmvqmn0PKzK1K5Hi4NAwtwd8jHJ4lILYOMzZUneZdKIzktF47","news_summary":"BioGenCell raises $16 million Seed round led by Marius Nacht for microvascular diseases treatment  CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"97ec9998-73e2-43bd-8b0a-2f53c0cf9d1f","date":"May 25, 2020","link":"https://biogencell.net/2020/05/25/biogencell-presented-its-promising-results-from-its-first-in-human/","source":"biogencell.net","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"8MizIebyhFKBl6tWuAyghMAO6V0yLyrmrxSNiRkiSSks2IujvhJwzP","news_summary":"Biogencell","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"8ec85566-a730-496e-a61c-595e31a22c17","date":"May 24, 2020","link":"https://www.firstwordpharma.com/node/1726878","source":"www.firstwordpharma.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"AiJnQDT8X3hxDYE4AFKO4TV0hPRVh6MsPARh458JJARzdx7kAsWDsK","news_summary":"BioGenCell Ltd. appoints New Chair and Strengthens Board of Directors","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d9c8d2f8-15a8-4d39-aad8-d16602e3a9ed","date":"May 14, 2020","link":"https://biogencell.net/2020/05/14/compassionate-treatment-against-all-odds/","source":"biogencell.net","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"yzGViJ1tnzDJBJUO9dfXPexa9z0Cj9ZWp1aM6ysDYQqwG5DaeSZrMZ","news_summary":"Biogencell","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"038a868c-1182-479c-a8d3-1b0e9cf1e7d3","date":"May 25, 2019","link":"https://biogencell.net/2019/05/25/biogencell-has-won-an-eu-competitive-grant-this-year-of-over-one-million-euros/","source":"biogencell.net","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"S9f03SgdofnuyRqqqaLnzu3bBt8JkiOHtj9adJSE8AktDKBRzMRk0e","news_summary":"Biogencell","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"7bcf56a0-165f-45fc-8b87-6fcee6b996a8","date":"May 25, 2019","link":"https://biogencell.net/2019/05/25/biogencell-has-opened-a-fully-owned-subsidiary-in-belgium/","source":"biogencell.net","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"qDBdmYl3lL6VSz9Q48ZAMGCSjYfmtVJAebLpvrHO11gj3FLCWNjOQW","news_summary":"Biogencell","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d3f7e9fd-0a28-4eee-8951-6b06ed04a095","date":"May 25, 2019","link":"https://biogencell.net/2019/05/25/biogencell-has-completed-the-6-months-follow-up/","source":"biogencell.net","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZP37BUtKxycsnThtfHAuVZESbhHmpa7WexHJEnb4YyNf07i4G5GDHq","news_summary":"Biogencell","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"df10e28a-d004-4b00-ae27-183855886211","date":"Nov 29, 2009","link":"http://www.globes.co.il/en/article-1000518140","source":"www.globes.co.il","visible":1,"analysis":{"tags":"stem cell, blood flow issues","company":"BiogenCell Ltd.","layoffs":null,"summary":"Stem cell start-up BiogenCell Ltd. has raised $1 million in funding. The company, founded a year ago, aims to treat blood flow problems in the limbs caused by diabetes and heart disease. BiogenCells unique product uses autologous cells derived from the patients themselves to repair blood vessels. The companys technology separates cells that have not yet undergone full cell speciation. BiogenCell is collaborating with physicians at Laniado Hospital in Netanya, Israel. The companys product is currently undergoing animal trials.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Stem cell","Blood flow issues","Autologous cells","Conference","Collaboration"],"date_of_event":"November 29, 2009","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YUFDEVyPRMUECoWbXfRoUNHGAiFV1Nad0p8GuRk50I5je3DPcFpDwS","news_summary":"Israeli stem cell co BiogenCell raises $1m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":10,"techcommunityinvolvement":null,"mediagallery":[{"id":"5c2bb71a-a9eb-4d45-8281-1b31d694e615","timestamp":"2019-09-03 11:36:49.000000","resources_type":2,"resources_title":"","resources_file_name":"2Ih4kEvTVHU","alt":"","imageurl":"https://img.youtube.com/vi/2Ih4kEvTVHU/0.jpg","url":"http://youtu.be/2Ih4kEvTVHU"}],"tags":["degenerative-diseases","stem-cells","hospitals","diabetes","therapeutics","cell-therapy","medical-technologies","biotechnology","personalized-medicine","clinics","doctors","healthcare-providers","cardiovascular","immunology","oncology","regenerative-medicine","stroke","cancer","treatments"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["BGC101"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$16M","totalrounds":4,"fundingstage":"Seed","totalfunding":"$18.35M","publicinvestors":1,"lastpublicfunding":16000000,"totalpublicrounds":4,"totalpublicfunding":18350000},"team":[{"name":"Yael Porat","email":"poratyael@gmail.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwNTC2IQJDA","bounced":false,"claimed":1,"founder":1,"urlname":"yael-porat-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA3vnytAgM","position":"Co-founder & CEO","last_name":"Porat","claimtoken":"f327c77ecefc24ce41ba6dd32acd01a83f296e08da188ac675a5e2c7a6ff3e43","first_name":"Yael","picturekey":"$9ucK4D8q4BdysiW7oJ2HcwBSHlM3EmhR1LWif0hKXFbduoxRI9jpkM","claimeddate":"2016-06-16","linkedinurl":"https://www.linkedin.com/in/yael-porat-29963611","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2015-04-14 07:33:27.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$9ucK4D8q4BdysiW7oJ2HcwBSHlM3EmhR1LWif0hKXFbduoxRI9jpkM","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eyal Peleg","email":"eyal.peleg@biogencell.net","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLLz1MkKDA","bounced":true,"claimed":0,"founder":1,"urlname":"eyal-peleg-5","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg8uSdjQkM","position":"Co-founder & CFO","last_name":"Peleg","claimtoken":"O2LdsEQe10NpctXkkxwncj97xmkEdm9fZD3ML3E5wXWOE31j7gloxh","first_name":"Eyal","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-10-20 13:09:06.000000","initials":"EP","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michael Belkin","email":"michael.belkin@biogencell.net","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLKpxdwLDA","bounced":true,"claimed":0,"founder":1,"urlname":"michael-belkin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg8vqMigkM","position":"Co-founder & CSO","last_name":"Belkin","claimtoken":"akokgcH54X0Zp41DptmoTYHjI7c4Mi8ANyvbvexXRBppIfAuErmGEw","first_name":"Michael","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michael-belkin-7651a8/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-10-20 13:09:08.000000","initials":"MB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN7UwIEIDA","fullname":"Aviv Alper"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2019-09-03T00:00:00.000Z","crunchbaseid":"biogencell","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-12-25T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Aviv Alper","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC8zdWeCww","date":"May 2022","amount":"$16M","source":"https://www.calcalistech.com/ctechnews/article/sywu8eil5","eventtype":"FundingRoundEvent","investment":[{"name":"Marius Nacht","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/marius-nacht","logokey":"$X1yMKnuiVvxHOA1IcEB08y2ysbZ8WxnyTHoZjPu7YZgZvuOZYs2mES","tagline":null,"urlname":"/investor_page/marius-nacht","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKeUtv8KDA","fundingtype":"Angel","leadpartner":null,"investmentid":"2cfc9a43-1805-4d60-96f1-f16654546d9c","fundingsubtype":"Angel","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X1yMKnuiVvxHOA1IcEB08y2ysbZ8WxnyTHoZjPu7YZgZvuOZYs2mES","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-zd7JCAw","date":"May 2019","amount":"$1.1M","source":"Company PR","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Service Public of Wallonia, DGO6","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/service-public-of-wallonia-dgo6","logokey":"$4BKnCsyO29grFYXogVpSnIgPRUNDSNYwS9V93J0u6cvdzqshdI85Pn","tagline":"","urlname":"/company_page/service-public-of-wallonia-dgo6","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jvzSCgw","fundingtype":"Other","leadpartner":null,"investmentid":"f1f1cad1-a77b-4776-8b25-7759d69f02a6","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4BKnCsyO29grFYXogVpSnIgPRUNDSNYwS9V93J0u6cvdzqshdI85Pn","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtoXVCQw","date":"Nov 2009","amount":"$1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkguieCAw","date":"","amount":"$250K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Michael Dezer","type":"Investor","amount":0,"hidden":true,"country":"Israel","fullurl":"/investor_page/michael-dezer","logokey":null,"tagline":"","urlname":"/investor_page/michael-dezer","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42-yqCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"742e1a54-398a-4db5-aaaa-0f18508b9985","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":250000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"12/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"BioGenCell","logourl":"https://storage.googleapis.com/clean-finder-353810/$aS2XYQbTtrPdtZop8CYJlfHTqbKJYqfoVuB9BUzepTXK3skNdHk42y","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$aS2XYQbTtrPdtZop8CYJlfHTqbKJYqfoVuB9BUzepTXK3skNdHk42y","seoabout":"BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"},{"title":"Patients","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Laboratories","key":"0-0-0-2","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Laboratories"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers","Patients","Laboratories","Life Sciences","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC8zdWeCww","date":"May 2022","amount":"$16M","source":"https://www.calcalistech.com/ctechnews/article/sywu8eil5","eventtype":"FundingRoundEvent","investment":[{"name":"Marius Nacht","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/marius-nacht","logokey":"$X1yMKnuiVvxHOA1IcEB08y2ysbZ8WxnyTHoZjPu7YZgZvuOZYs2mES","tagline":null,"urlname":"/investor_page/marius-nacht","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKeUtv8KDA","fundingtype":"Angel","leadpartner":null,"investmentid":"2cfc9a43-1805-4d60-96f1-f16654546d9c","fundingsubtype":"Angel","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X1yMKnuiVvxHOA1IcEB08y2ysbZ8WxnyTHoZjPu7YZgZvuOZYs2mES","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtoXVCQw","date":"Nov 2009","amount":"$1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-zd7JCAw","date":"May 2019","amount":"$1.1M","source":"Company PR","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Service Public of Wallonia, DGO6","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/service-public-of-wallonia-dgo6","logokey":"$4BKnCsyO29grFYXogVpSnIgPRUNDSNYwS9V93J0u6cvdzqshdI85Pn","tagline":"","urlname":"/company_page/service-public-of-wallonia-dgo6","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jvzSCgw","fundingtype":"Other","leadpartner":null,"investmentid":"f1f1cad1-a77b-4776-8b25-7759d69f02a6","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4BKnCsyO29grFYXogVpSnIgPRUNDSNYwS9V93J0u6cvdzqshdI85Pn","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkguieCAw","date":"","amount":"$250K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Michael Dezer","type":"Investor","amount":0,"hidden":true,"country":"Israel","fullurl":"/investor_page/michael-dezer","logokey":null,"tagline":"","urlname":"/investor_page/michael-dezer","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42-yqCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"742e1a54-398a-4db5-aaaa-0f18508b9985","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":250000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}